drugset / Trial / NCT01092754
Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Optimark (Gadoversetamide) in Pediatric Patients
Non-randomizedParallel-groupOpen-labelDiagnostic
Summary
The objective of this study is to characterize the safety, efficacy and pharmacokinetic profiles of Optimark at the standard clinical dose of 0.1 mmol/kg in the pediatric patient population.
Timeline
- Start
- 2002-05
- Primary completion
- 2003-12
- Completion
- 2003-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gadoversetamide | Diagnostic / imaging agent | 0.1 mmol | Intravenous |
Indications
No indication recorded.